| 1 | paladin labs inc announces | | | | | | | 4 | 0.97% |
| 2 | labs inc to commercialize | | | | | | | 3 | 0.73% |
| 3 | paladin labs inc to | | | | | | | 3 | 0.73% |
| 4 | contact customer service medical | | | | | | | 2 | 0.49% |
| 5 | investigator initiated research grants | | | | | | | 2 | 0.49% |
| 6 | grants program investigator initiated | | | | | | | 2 | 0.49% |
| 7 | fellowship grants program investigator | | | | | | | 2 | 0.49% |
| 8 | and fellowship grants program | | | | | | | 2 | 0.49% |
| 9 | grants community grants our | | | | | | 2 | 0.49% |
| 10 | community grants our products | | | | | | 2 | 0.49% |
| 11 | investors news and events | | | | | | | 2 | 0.49% |
| 12 | inc investors news and | | | | | | | 2 | 0.49% |
| 13 | endo inc investors news | | | | | | | 2 | 0.49% |
| 14 | team endo inc investors | | | | | | | 2 | 0.49% |
| 15 | management team endo inc | | | | | | | 2 | 0.49% |
| 16 | community contact customer service | | | | | | 2 | 0.49% |
| 17 | research grants community grants | | | | | | 2 | 0.49% |
| 18 | a highly focused generics | | | | | | | 2 | 0.49% |
| 19 | labs inc announces approval | | | | | | | 2 | 0.49% |
| 20 | inc announces the launch | | | | | | | 2 | 0.49% |
| 21 | for paladin labs inc | | | | | | | 2 | 0.49% |
| 22 | announces the launch of | | | | | | | 2 | 0.49% |
| 23 | highly focused generics and | | | | | | | 2 | 0.49% |
| 24 | inc announces approval of | | | | | | | 2 | 0.49% |
| 25 | with advanced parkinsons disease | | | | | | | 1 | 0.24% |
| 26 | transplant patients is now | | | | | | | 1 | 0.24% |
| 27 | patients is now reimbursed | | | | | | | 1 | 0.24% |
| 28 | is now reimbursed in | | | | | | | 1 | 0.24% |
| 29 | manitoba and saskatchewan 23oct2019 | | | | | | | 1 | 0.24% |
| 30 | patients with advanced parkinsons | | | | | | | 1 | 0.24% |
| 31 | for patients with advanced | | | | | | | 1 | 0.24% |
| 32 | now reimbursed in ontario | | | | | | | 1 | 0.24% |
| 33 | reimbursed in ontario quebec | | | | | | | 1 | 0.24% |
| 34 | 23oct2019 movapo® apomorphine hydrochloride | | | | | | | 1 | 0.24% |
| 35 | saskatchewan 23oct2019 movapo® apomorphine | | | | | | | 1 | 0.24% |
| 36 | and saskatchewan 23oct2019 movapo® | | | | | | | 1 | 0.24% |
| 37 | canadian provinces 31jul2019 helsinn | | | | | | | 1 | 0.24% |
| 38 | advanced parkinsons disease now | | | | | | | 1 | 0.24% |
| 39 | inc to commercialize pracinostat | | | | | | | 1 | 0.24% |
| 40 | tablets in canada 25jul2018 | | | | | | | 1 | 0.24% |